These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29528485)

  • 1. Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study.
    Irwin SL; Qubty W; Allen IE; Patniyot I; Goadsby PJ; Gelfand AA
    Headache; 2018 May; 58(5):724-731. PubMed ID: 29528485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).
    Starling AJ; Tepper SJ; Marmura MJ; Shamim EA; Robbins MS; Hindiyeh N; Charles AC; Goadsby PJ; Lipton RB; Silberstein SD; Gelfand AA; Chiacchierini RP; Dodick DW
    Cephalalgia; 2018 May; 38(6):1038-1048. PubMed ID: 29504483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis.
    Lloyd JO; Hill B; Murphy M; Al-Kaisy A; Andreou AP; Lambru G
    J Headache Pain; 2022 Jun; 23(1):63. PubMed ID: 35668368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.
    Lipton RB; Dodick DW; Silberstein SD; Saper JR; Aurora SK; Pearlman SH; Fischell RE; Ruppel PL; Goadsby PJ
    Lancet Neurol; 2010 Apr; 9(4):373-80. PubMed ID: 20206581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program.
    Bhola R; Kinsella E; Giffin N; Lipscombe S; Ahmed F; Weatherall M; Goadsby PJ
    J Headache Pain; 2015; 16():535. PubMed ID: 26055242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W; Shaw J; Bloom M; Gebeline-Myers C
    Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
    Apostol G; Lewis DW; Laforet GA; Robieson WZ; Fugate JM; Abi-Saab WM; Saltarelli MD
    Headache; 2009 Jan; 49(1):45-53. PubMed ID: 19040679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial.
    Powers SW; Coffey CS; Chamberlin LA; Ecklund DJ; Klingner EA; Yankey JW; Peugh JL; Korbee LL; Simmons K; Sullivan SM; Kabbouche MA; Kacperski J; Porter LL; Reidy BL; Hershey AD
    JAMA Netw Open; 2021 Jul; 4(7):e2114712. PubMed ID: 34251445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.
    Silberstein SD; Calhoun AH; Lipton RB; Grosberg BM; Cady RK; Dorlas S; Simmons KA; Mullin C; Liebler EJ; Goadsby PJ; Saper JR;
    Neurology; 2016 Aug; 87(5):529-38. PubMed ID: 27412146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of continuous theta burst stimulation of the primary motor cortex in reducing migraine frequency: A preliminary open-label study.
    Chen PR; Lai KL; Fuh JL; Chen SP; Wang PN; Liao KK; Wang SJ
    J Chin Med Assoc; 2016 Jun; 79(6):304-8. PubMed ID: 26874681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.
    Leuchter AF; Cook IA; Feifel D; Goethe JW; Husain M; Carpenter LL; Thase ME; Krystal AD; Philip NS; Bhati MT; Burke WJ; Howland RH; Sheline YI; Aaronson ST; Iosifescu DV; O'Reardon JP; Gilmer WS; Jain R; Burgoyne KS; Phillips B; Manberg PJ; Massaro J; Hunter AM; Lisanby SH; George MS
    Brain Stimul; 2015; 8(4):787-94. PubMed ID: 26143022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.
    Kinfe TM; Pintea B; Muhammad S; Zaremba S; Roeske S; Simon BJ; Vatter H
    J Headache Pain; 2015; 16():101. PubMed ID: 26631234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcranial Magnetic Stimulation: Basic Principles and Clinical Applications in Migraine.
    Barker AT; Shields K
    Headache; 2017 Mar; 57(3):517-524. PubMed ID: 28028801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.
    Wilkinson D; Ade KK; Rogers LL; Attix DK; Kuchibhatla M; Slade MD; Smith LL; Poynter KP; Laskowitz DT; Freeman MC; Hoffer ME; Saper JR; Scott DL; Sakel M; Calhoun AH; Black RD
    Headache; 2017 Jul; 57(7):1065-1087. PubMed ID: 28656612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.